This work presents a rational approach to engineering BCMA-CD24-CAR-T cells that not only effectively target bulk MM tumor cells, but also substantially reduce the numbers of minimal residual MM cells and modulate the tumor microenvironment (Fig. 7). This evidence concerns the gene CD24 and neoplasm.